SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/iPhecsJeJX https://t.co/0TIy2hsPC1

Link Between Vitamin D and Psoriasis Severity More than 8M people in the US experience psoriasis-a person’s vitamin D levels could play an important role in psoriasis severity, according to one of the largest studies to date. https://t.co/bHnYn87wQS https://t.co/JsloVaxHd4

Rheumatoid vasculitis (RV) metanalysis: RV decreased sincefrom 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/O3G4CS1pdx https://t.co/I2RVKR20lX

Voclosporin in SLE - Long-Term Safety and Efficacy The AURORA 2 study evaluated the long-term safety and efficacy of VOC upus nephritis (LN) patients and, after 3 years, demonstrated long term safety and efficacy following the one-year AURORA 1 study. https://t.co/YmKLuhyCVG https://t.co/X2u9iCckt7

EULAR/ACR Guidance on HLH/MAS A EULAR/ACR task force has established evidence based, up-to-date guidance, and expert opinion on the evaluation, management and monitoring of patients with HLH and MAS. https://t.co/ZQQ75pyvAX https://t.co/t6lj5XaAwB

SGLT2 Inhibitors Reduce Gout Flares and CV Events A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/XCh7ulamwU https://t.co/dbOAtaflmb

JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/8U6DHbJybE https://t.co/e45KCd5gBL

MMWR: Arthritis Among Children and Adolescents The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021. https://t.co/S1dG60jJ1J https://t.co/rKQ64sopl2

RNase Treatment of Autoimmune Disorders U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. https://t.co/RuXV3uAVz7 https://t.co/rWaKlmPnEe

Tofactitinib in PsA & RA: Nine Year Safety Data A real-world, post-marketing surveillance (PMS) of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified. https://t.co/erBi7JJtCY https://t.co/9tU361FkfU

Time to live your life. Do the right thing, make a difference, leave an imprint.. https://t.co/LEY7bFcV2S

Horizon announced its phase II RCT of Daxdilimab (anti-ILT7 mAB targeting dendritic cells) failed to meet its primary endpoint - BICLA response w/ pred ≤7.5 mg/day @wk48 (DAX=PBO). DAX also under study in alopecia areata, DLE, lupus nephritis https://t.co/8zDCWI5vB1 https://t.co/pVIg4ctvC5